Sign up to The Irish Times Archive (1859 - 2008)My Account »
Tue 11 Nov 2009Fears emerge over weight-loss drug's links with kidney damage
THE EUROPEAN Medicines Agency has recommended the product information for the widely used weight-loss drug Alli be updated after kidney and pancreatic problems were reported in a number of patients using the drug.
In its latest monthly report, the EMEA’s Committee for Medicinal Products for Human Use (CHMP) said that it had recommended changes to the usage guidelines following an assessment of the “adverse events” associated with the drug.
Choose a Subscription type - required
